Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

<p>Persistence of Tcm-derived CD19-CAR T cells</p>

Kaydedildi:
Detaylı Bibliyografya
Yazar: Ibrahim Aldoss (15055961) (author)
Diğer Yazarlar: Samer K. Khaled (15055964) (author), Xiuli Wang (15055967) (author), Joycelynne Palmer (15055970) (author), Yan Wang (15055973) (author), Jamie R. Wagner (15055976) (author), Mary C. Clark (15055979) (author), Jennifer Simpson (15055982) (author), Jinny Paul (15055985) (author), Vibhuti Vyas (15055988) (author), Sheng-Hsuan Chien (15055991) (author), Anthony Stein (15055994) (author), Vinod Pullarkat (15047900) (author), Amandeep Salhotra (15055997) (author), Monzr M. Al Malki (15056000) (author), Ahmed Aribi (15056003) (author), Karamjeet Sandhu (15056006) (author), Sandra H. Thomas (15056009) (author), Lihua E. Budde (15056012) (author), Guido Marcucci (11252666) (author), Christine E. Brown (15056015) (author), Stephen J. Forman (15056018) (author)
Baskı/Yayın Bilgisi: 2025
Konular:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Hematological Cancers
Leukemias
Immunotherapy
Cellular immunotherapy
Engineered/CAR T cells
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
Diğer Bilgiler
Özet:<p>Persistence of Tcm-derived CD19-CAR T cells</p>

Benzer Materyaller